Here is a summary of the data for Utah : Share of all patients who take a GLP-1: 0.7% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.4% Share of female patients with an obesity diagnosis who take a GLP-1: 5.1% Share of GLP-1 users that are female: 60.4% For reference, here are the statistics for the entire United States: Share of all patients who take a GLP-1: 1.0% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.2% Share of female patients with an obesity diagnosis who take a GLP-1: 5.2% Share of GLP-1 users that are female: 64.7% For more information, a detailed methodology, and complete results, see U.S
Injectable Wegovy dosage schedule Wegovy (the brand name for the drug semaglutide thats FDA-approved for weight management) comes in two forms, as a daily pill (more on that below), or as a weekly injection that comes in six strengths, from 0.25mg to 7.2mg
Obesity is a serious and common health issue that was misunderstood for a very long time
10.1124/jpet.104.073890 198
Half-life of ipamorelin is between 2-3 hrs
Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J
